Treatment Breakthroughs In AML
|
|
- Alfred Greene
- 8 years ago
- Views:
Transcription
1 Treatment Breakthroughs In AML Martin S. Tallman, M.D. Chief, Leukemia Service Memorial Sloan-Kettering Cancer Center Weill Cornell Medical College New York, NY Hong Kong 212
2 Outline Introduction Overview of current therapy Breakthroughs Future Directions
3 Introduction Median age of AML: 72 years New patients/deaths in 211: 13,4/9, De novo or therapy-related or evolved from MDS or MPN Outcome varies by prognostic factors Heterogeneity in genetics and clinical manifestations Ca for Clinicians, 29; Juliusson Blood, 29
4 Overview of Current Therapy
5 Survival of Newly Diagnosed AML Consecutive ECOG Frontline Trials Age P r o b a bi lit y n=2, Age > 55 P r o b a bi lit y n=1, Year Year Tallman, Gilliland, Rowe et al. Blood, 25 and update
6 AML in Older Adults (>6) Overall Survival with Unfavorable Cytogenetics 1 O v e r al l S u rv iv al ( % ) Years GAMLCG Data HAM-HAM TAD-HAM n= Buchner et al. J Clin Oncol, 26
7 Breakthroughs Gene discovery/prognostic factors Acute promyelocytic leukemia (ATRA/ATO) Drug development Induction/postremission Minimal residual disease Less intense treatment of older adults Transplantation/alternative donors
8 Gene Discovery/Prognostic Factors
9 Distribution of Cytogenetically and Molecularly Defined Risk Groups in AML 14% Other 5% MLL- adverse 3% PTD inv(3)/t(3;3)/evi-1 ADVERSE 34% 12% FLT- ITD/ NPM1 wt INTERMEDIATE 21% t(15;17)/pml-rara 11% t(8;21)/runx1- RUNX1-T1 8% Inv(16)/t(16;16)/ CBFB-MYH11 5% FAVORABLE 45% NPM1 mut/ FLT3- ITD neg/wt1 wt 18% CEBPA mut (biallelic)/ FLT3-ITD neg 3% Grimwade Hematology Am Soc Hematol Educ Program,
10 Mutation Frequencies 398 Patients on ECOG Protocol E19 For Younger de novo AML Mutation Frequency IDH1 6% IDH2 8% TET2 1% ASXL1 4% FLT3 37%* NPM1 24% KIT 14% CEBP 9% WT1 1% KRAS 2.5% NRAS 1% *ITD 3%,TKD 7% Patel et al. N Engl J Med 212 (in press)
11 Mutation Mutation Frequencies in Normal Karyotype AML Frequency NPM1 53% (fav) FLT3-ITD 31% FLT3-TKD 11% CEBP 15% (fav) MLL-PTD 8% NRAS 13% IDH1/2 1/3% Schlenk et al N Engl J Med, 28; Boissel et al. J Clin Oncol, 21
12 Abbas et al. Blood, 21; Ley et al. N Engl J Med, 21; Nibourel et al. Blood, 21; Chou et al. Blood, 21; Patel et al. ASH, 21 Novel Mutations in AML Mutation Freq Associations Outcome IDH1/2 6%/8% Older age, NK, NPM1+ Decreased OS in FLT3-/NPM1- DNMT3A 22% TET2 1% Enriched in intermedrisk, absent in fav-risk May be assoc. with NPM1+ Decreased OS Decreased OS in intermed-risk, FLT3- ASXL1 4% Older age, RUNX1, trisomy 8 and not complex cyto, FLT3, NMP1, WT1; CEBP Decreased OS in intermed-risk, FLT3-
13 TET2 and ASXL1 Mutations Associated With Adverse Outcom in Intermediate-Risk, FLT3-ITD WT AML Intermediate Risk, FLT3-ITD WT AML 15 P e 1 r c e 5 n t s u r OS v (Days) Intermediate Risk, FLT3-ITD WT AML i v 15 ap le 1 r c e n t s u r OS 15 2 TET2 WT TET2 Mutant P<.1 ASXL1WT ASXL1Mutant P=.1 25!!!!! Patel et al. N Engl J Med, 212 (in press)
14 IDH/NPM1 Mutations Define Favorable Outcome in FLT3-Neg, Intermediate-Risk AML 1..8 NPM1/IDH double mutant NPM1-mutant, IDH-WT P< IDH/NPM1-mutant pts, but not NPM1-mutant/IDH-WT pts have a favorable outcome Patel et al. N Engl J Med, 212 (in press)
15 Inducton/Postremission
16 Dauno Dose Intensification E19 AML < 6 yrs Induction DNR 45 mg/m2 x 3 days Post -Remission Observation AML + Cytarabine 1mg/m2 x 7 days 1-2 course to CR High-dose Cytarabine x 2 Auto HCT DNR 9 mg/m2 x 3 days Sibling Allogeneic HCT Gemtuzumab Ozogamicin Fernandez et al. N Engl J Med, 29
17 Intensified Induction in AML ECOG E patients CR Dauno 45-57% Dauno 9-71% p=<.1 Induction deaths Dauno % Dauno 9-4% p=.28 Fernandez et al. N Engl J Med, 29
18 Dauno Dose Intensification: E19 Overall Survival P r o b a b i l i t y Log Rank Test p= All Patients 3 4 Month Induction Treatment 45 mg/m2/day 9 mg/m2/day N=33 5 N= Pr ob ab ilit y Pr ob ab ilit y Favorable and Intermediate Cytogenetics Log Rank Test p= Log Rank Test p=.45 Month Unfavorable Cytogenetics Month N=178 N=18 N=63 N=59 Fernandez et al. N Engl J Med,
19 DNMT Mutational Status Does Not Affect Outcome in E19 Cohort DNMT- MT DNMT- WT P= Patel et al. N Engl J Med, 212 (in press)
20 High Dose Daunorubicin Improves Outcome in DNMT3A Mutant Patients, But Not DNMT-WT patients DNMT3A-WT pts DNMT3A-MT pts Standard Dose High Dose P= P= Patel et al. N Engl J Med, 212 (in
21 High Dose Daunorubicin Improves Outcome in Patients With DNMT3A Mutations, MLL Fusions, or NPM1 Mutations At Risk DNMT3A/MLL/NPM1-WT pts P= Std Dose High Dose DNMT3A, MLL, NPM1 mutant Standard Dose High Dose P= At Risk Std Dose High Dose Patel et al. N Engl J Med, 212 (in press)
22 Gemtuzumab Ozogamicin Structure Humanized anti-cd33 antibody linked to calicheamicin History Induces CR/CRp ~ 3% Approved for adults > 6 in first relapse in 2 (dose 9 mg/m2 twice) Rare VOD/SOS Withdrawn from market in 21
23 Variable Results From Randomized Trials of Gemtuzumab Ozogamicin in AML (age <6) MRC AML15 (3 mg/m2/dose/cycle) No increase in induction mortality Survival benefit in fav-risk Trend for survival benefit in intermed-risk SWOG S16 (6 mg/m2/dose/cycle) Increased induction mortality Trend for survival benefit in fav-risk Burnett et al. J Clin Oncol, 211; Petersdorf et al. Blood, 29 (abstr)
24 Fractionated Gemtuzumab Ozogamicin + Chemotherapy in De Novo AML ALFA 71 Patients aged 5-7 yrs with de novo AML (N = 278) Induction GO 3 mg/m2/day on Days 1, 4, and 7 + Dauno/ Cytarabine (n = 139) Dauno/ Cytarabine Consolidation (2 courses) GO 3 mg/m2/day on Day 1 + Dauno/ Cytarabine Dauno/ Cytarabine Castaigne et al. ASH 211 (abstr)
25 ALFA 71 EFS E F S p r o b a b ili t y GO + Daunorubicin/Cytarabine Daunorubicin/Cytarabine D/C GO + D/C EFS P =.18 D/C (n=139) Events GO + D/C (n=139) Median 11.9 mo 19.6 mo 2-year 16.5% 41.1% months Castaigne et al. ASH 211 (abstr)
26 ALFA 71 GO + dauno/cytarabine improved EFS, OS, RFS in AML aged 5-7 (fav and interm cyto) Safety profile of GO acceptable despite increase in hematologic and liver toxicity Castaigne et al. ASH 211 (abstr)
27 mtuzumab Ozogamicin (GO) In Induction C AML15 Induction Consolidation DA GO vs ADE GO vs FLAG-Ida GO MACE-MiDAC GO vs HiDAC GO (3. vs 1.5 mg/m2) Burnett et al. Blood, 29 (abstr)
28 MRC AML15 Post-remission Outcomes 5-yr death in CR 5-yr relapse rate 5-yr RFS 5-yr OS Ara-C 1% 53% 42% 54% MRC 15% 51% 42% 52% Ara-C 1.5 gm 9% 58% 38% 54% Ara-C 3 gm 14% 51% 43% 52% 5 courses % 58% 42% 6% 4 courses 1% 53% 46% 58% Burnett et al. Blood, 29 (abstr)
29 MRC AML 15 Ara-C dose % S ti ll A li v e AraC 3g AraC 1.5g 1 Overall Survival from Consolidation N Events Years from entry 2P =.7 54 % 52 % 5 % S ti ll A li v e AraC 3g AraC 1.5g 1 N Relapse-Free Survival from Consolidation Events Years from entry 2P =.5 42 % 38 % 5 % S ti ll A li v e AraC 3g AraC 1.5g 1 Relapse Risk from Consolidation N Events Years from entry 2P =.2 59 % 51 % 5 % S ti ll A li v e AraC 3g AraC 1.5g 1 Death in CR from Consolidation N Events 2P = Years from entry 14 % 8% Burnett et al. Blood, 29 (abstr) 5
30 OS of CR Patients Randomized to Receive Consolidation Therapy P r o b a bi lit y P= High-dose Ara-C arm Conventional standard-dose arm P.8 r.6 o Conventional standard-dose b.4 arm a.2 bi P=.7 lit 1 y Years High-dose Ara-C arm Conventional standard-dose=2 mg/m2 D1-5 x 4 High-dose Ara-C= 2. gm/m2 q12h D1-5 x 3 Ohtake et al. Blood, 211
31 Induction and Postremission Strategies High-dose daunorubicin appears better for younger patients in induction GO may benefit CBF AML/fav-risk Lower doses of ara-c appear as good as standard HiDAC for consolidation and potentially less toxic HiDAC in consolidation may not benefit intermedand high-risk patients
32 Drug Development
33 New Agents in AML Agent Mechanism Comments CPX-351 DOT1L inhibitor Liposomal fixed ratio of dauno/ara-c Histone H3K79 methyltransferase High response rate and reduced mortality Preclinical data against MLL Sorafenib/AC22 Multikinase inhib CRs w/single agent Clofarabine Nucleoside analog Effective in older adults with unfav. prog. factors Sapacitabine Nucleoside analog CRs w/single agent Elacytarabine Eliadic ester of ara-c Modest remission in adv disease Bayne J Pharm Sci, 28; Pollock ASH, 21; Metzelder Blood, 29; Cortes Blood, 29 (abstr); Erba J Clin Oncol, 21; Kantarjian Blood, 29 (abstr); O Brien Blood, 29 (abstr)
34 CPX-351 A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed Ratio DSPC DSP Cholesterol Cytarabine Daunorubicin G 1 nm bilamellar liposomes 5:1 molar ratio of cytarabine to daunorubicin 1 unit = 1. mg cytarabine plus.44 mg daunorubicin Specifically designed drug delivery vehicle enables specific drug ratios to be maintained Feldman et al. J Clin Oncol, 211
35 CPX-351 vs Remission Rates CPX n=84 n=41 CR+CRi 56 (66.7%) 21 (51.2%) p=.712** CR 41 (48.8%) 2 (48.8%) CRi 15 (17.9%) 1 (2.4%) **one-sided Fisher s Exact test Lancet et al. ASH,
36 CPX-351 vs Early Deaths (all causes) CPX n=85 n=41 3-Day Mortality 3 (3.5%) 3 (7.3%) p=.35 6-Day Mortality 4 (4.7%) 6 (14.6%) p=.53 All early deaths occurred in the high risk group Lancet et al. ASH, 21
37 CPX-351 vs Event-Free and Overall Survival Event Free Survival Overall Survival 1% 8% 6% Logrank p-value =.11 CPX-351 1% 8% 6% 7+3 Logrank p-value =.61 CPX-351 4% 7+3 4% 2% 2% % % Months from randomization Months from randomization Lancet et al. ASH, 21
38 CPX-351 vs Event Free and Overall Survival Secondary AML Event-Free Survival Overall Survival 1% 8% 6% 4% 2% 7+ 3 Logrank p-value =.7 CPX % 8% 6% 4% 2% % % Months from randomization 7+ 3 Logrank p-value =.1 CPX- 351 Months from randomization Lancet et al. ASH, 21
39 Quizartinib Monotherapy in Relapsed/ Refractory FLT3-ITD Positive AML Quizartinib (AC22), a selective oral FLT3 TKI active in FLT3-ITD pos AML Nonrandomized phase II trial of quizartinib monotherapy ongoing 2 patient cohorts enrolled Cohort 1 Relapsed/refractory to frontline chemo Age 6 years Cohort 2 Relapsed/refractory to second-line chemo or HSCT Age 18 years Cortes et al. ASH, 211 (abstr)
40 Quizartinib in Relapsed/Refractory FLT3-ITD Positive AML Efficacy Best Response, % CRc (CR + CRp + CRi) Cohort 1 (n = 26) Cohort 2 (n = 36) Total (N = 62)! CR 4 2! CRp 4 2! CRi PR NR Unknown Cortes et al. ASH 211, (abstr)
41 Early Detection of MRD as a Potential Tool For Risk-Stratification in AML Flow cytometry San Miguel et al. Blood MRD post-induction 1 RQ-PCR (WT1) Cilloni et al. J Clin Oncol 29 <2 log reduction >= log reduction % i n C R < 5x1-3 (n=24) 5x1-3 (n=18) p=. 1 R e l a p si n g % n=35 n=56 p=.4 75% 4% Months 1 2 Years 3 4 5
42 Treatment of Older Adults
43 Treatment of Older Adults Agent N Med Age CR Mortality OS 5-azacitidine % NA 25 mo Decitabine % 7% 7.7 mo Lenalidomide* %** 24% 4 mo Clofarabine % 1% 1 mo *5 mg/m2 for up to two 28-day cycles **53% CR+CRi aux et al. J Clin Oncol, 29; Cashen et al. J Clin Oncol, 21; Fehniger et al. Blood, 21; tarjian et al. Clin Oncol, 21
44 Overall Survival in Patients Receiving Azacitidine or Conventional Care Regimens P at ie nt S u rv iv al ( p r o p o rti o n ) % 24.5 mo 16. mo Azacitidine 16% CCR Time Since Random Assignment (months) Fenaux et al. J Clin Oncol, 29
45 Treatment of Older Adults Prognostic factor models exist to predict induction mortality, CR and OS Novel strategies exist with potentially less toxicity and unique mechanisms of action Further studies will define optimal dose and schedule and combinations Important shift away for conventional chemotherapy toward novel strategies-new standard of care
46 Transplantation/Alternative Donors
47 Advances in Transplantation Equivalent outcomes MSD and MUD Haploidentical transplantation Umbilical cord Reduced-intensity conditioning Outcome of t-aml
48 Leukemia-Free Survival by Donor Type For Patients With Heme Malignancy in CR 1,2 or 3 C u m ul at iv e P r o p o rti o n MM URD (n=52) DUCB (n=128) SIB (n=24) P =.19 MUD (n=152) Years post-transplantation Brunstein et al. Blood,
49 Probability of Overall Survival After Allogeneic HCT for Therapy-Related AML and MDS by Risk Factors 1 Prob at 5 yrs p<.1 P r o b a b ili t y, % risk factors 4% (N=25) Risk Factors 1. Age >35 2. Poor-risk cytogenetics 3. t-aml not in CR or adv MDS 4. Donor other than MDS or well-matched MUD Year s risk factors 5% (N=82) 1 risk factor 25% (N=293) 2 risk factors 19% (n=29 3 risk factors 12%(N=178) Litzow et al. Blood, 21
50 Transplantation For AML in CR1 Alternative donor sources expand pool of patients who may benefit Outcome for MUD transplants appears to approach that of MRD Umbilical cord transplantation increasing Identify pts with t-aml who may or may not benefit from transplant
51 Future Directions in AML Gene expression profiling for signatures characteristic of specific genetic subtypes, identify cooperating mutations and perturbed pathways and predict treatment response Risk-stratify therapy with specific targeted strategies Characterize mechanisms of action and off-target effects of putative molecularly targeted therapies Identify molecular markers of residual disease
52 Acknowledgments ECOG Leukemia Committee North American Intergroup Colleagues European LeukemiaNet Colleagues Leukemia Service Memorial Sloan-Kettering Cancer Center
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES 56 AML Unmet Medical Need, Current Therapies and Current Pipeline Martin S. Tallman, M.D. Chief, Leukemia Service Memorial
More informationLEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova
LEUCEMIA MIELOIDE ACUTA A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova Impact of mutational analysis in AML C. Thiede Optimal acute myeloid leukemia therapy in 2012 H. Dombret Acquired
More informationRisk Stratification in AML. Michelle Geddes Feb 27, 2014
Risk Stratification in AML Michelle Geddes Feb 27, 2014 Objectives Outline the challenges in post-remission therapy for AML Review etiology of disease escape mechanisms from therapy Evaluate prognostic
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Upfront Therapy in Newly Diagnosed Elderly AML Patients: Is Decitabine (DAC) the new standard? Raoul Tibes, MD, PhD Senior Associate Consultant, Mayo Clinic Arizona Associate Director,
More informationClinical Use of Karyotype and Molecular Markers In Curing Acute Myeloid Leukemia
Clinical Use of Karyotype and Molecular Markers In Curing Acute Myeloid Leukemia Clara D. Bloomfield, M.D. Distinguished University Professor The Ohio State University Comprehensive Cancer Center, and
More informationAML- new studies. Moderator Prof. Edo Vellenga. 1st author / speaker Mojca Jongen-Lavrencic
AML- new studies Moderator Prof. Edo Vellenga 1st author / speaker Mojca Jongen-Lavrencic Belangenverklaring In overeenstemming met de regels van de Inspectie van de Gezondheidszorg (IGZ) Naam: Organisatie:
More informationAcute Leukemia: AML, APL and ALL. Martin S. Tallman, M.D. Memorial Sloan-Kettering Cancer Center Weill Cornell Medical College New York, NY
Acute Leukemia: AML, APL and ALL Martin S. Tallman, M.D. Memorial Sloan-Kettering Cancer Center Weill Cornell Medical College New York, NY 11 th Annual Indy Hematology Review March, 2015 Practice Changing
More informationOriginal Article Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus
Am J Blood Res 2013;3(2):141-164 www.ajblood.us /ISSN:2160-1992/AJBR1301001 Original Article Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus Joseph M Brandwein 1, Michelle
More informationTreatment of acute myeloid leukemia: are we making progress?
HAM-WASSERMAN LECTURE Treatment of acute myeloid leukemia: are we making progress? Alan K. Burnett 1 1 School of Medicine, Cardiff University, Cardiff, United Kingdom With a few subgroups as exceptions,
More informationAPPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen
APPROACH TO THE DIAGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Hematology Rounds Thurs July 23, 2009 Carolyn Owen Outline Diagnosis Prognosis Treatment AML Elderly AML APL Future directions AML
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationCurative treatment in acute myeloid leukemia (AML)
ACUTE MYELOID LEUKEMIA Optimal induction and post-remission therapy for AML in first remission Jacob M. Rowe 1 1 Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion,
More informationAML: How to characterize and treat elderly patients non fit for standard chemotherapy
m1 AML: How to characterize and treat elderly patients non fit for standard chemotherapy Clinic for Medicine III University Hospital Munich Campus Grosshadern AMLCG study group Karsten Spiekermann, MD
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationPan Birmingham Cancer Network: Haematology NSSG Chemotherapy Regimens AML intensive v1.0 August 2010
AML - TRIALS It is best practise for all patients to be treated on the appropriate NCRI national trial for AML. It is outside of the remit for this regimen list to provide a comprehensive detail of the
More informationREFERENCE CODE GDHC003POA PUBLICAT ION DATE AUGUST 2013
REFERENCE CODE GDHC003POA PUBLICAT ION DATE AUGUST 2013 ACUTE MYELOID LEUKEMIA (AML) - Executive Summary AML: Key Metrics in Six Major Pharmaceutical Markets, 2012 2017 2012 Epidemiology Incident Population
More informationCI-1. DACOGEN (decitabine) United States Food and Drug Administration Oncologic Drugs Advisory Committee February 9, 2012 NDA #21790/S-010
CI-1 DACOGEN (decitabine) United States Food and Drug Administration Oncologic Drugs Advisory Committee February 9, 2012 NDA #21790/S-010 CI-2 Introduction Alton Kremer, MD, PhD Senior Vice President,
More informationAcute Myeloid Leukemia: Focus on Novel Therapeutic Strategies
Clinical Medicine Insights: Oncology Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Acute Myeloid Leukemia: Focus on Novel Therapeutic Strategies
More informationTherapy of AML. Contents. 1.1 Introduction... 1
Therapy of AML Elihu Estey Contents 1.1 Introduction... 1 1.2 Standard Therapy... 2 1.2.1 3+7... 2 1.2.2 Outcome Following 3+7... 2 1.2.3 Predictors of TRD... 2 1.2.4 Cytogenetics as the Principal Predictor
More informationMDS/AML and epigenetics
MDS/AML and epigenetics Moderator Prof.dr. J.H.E. Kuball 1st author / speaker Dr. G. Huls Belangenverklaring In overeenstemming met de regels van de Inspectie van de Gezondheidszorg (IGZ) Naam: Organisatie:
More informationStem Cell Transplantation for Acute Lymphoblastic Leukemia
Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic
More informationFrom Genome to Medicine - Acute Myeloid Leukemia
From Genome to Medicine - Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University, Germany DGIM Opinion Leader
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationGuideline 12-9. A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment of Acute Myeloid Leukemia (AML) Andre C Schuh, Glenn G Fletcher, Brian Leber, Mitchell Sabloff,
More informationTreating Minimal Residual Disease in Acute Leukemias: How low should you go?
Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Ramsie Lujan, Pharm.D. PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Pharmacotherapy Education and
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Clinical Development Program Prof. Moshe Phillip, MD VP Clinical & Medical Affairs 1 Rationale for BL-8040 Development
More informationPr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
More informationTreatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationPROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
More informationStakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
Brochure More information from http://www.researchandmarkets.com/reports/1088137/ Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Description: The drug therapy of acute
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationAcute Myeloid Leukemia Therapeutics Market to 2020
Brochure More information from http://www.researchandmarkets.com/reports/3030124/ Acute Myeloid Leukemia Therapeutics Market to 2020 Description: Summary: Treatment and prognosis in AML is strongly influenced
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationDNA Methylation in MDS/MPD/AML: Implications for application
DNA Methylation in MDS/MPD/AML: Implications for application James G. Herman, M.D. Professor of Oncology Evelyn Grollman Glick Scholar The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Disclosures
More informationThe phrase divide and conquer is thought to be derived
Clinical Review & Education Review A Contemporary Review Tapan M. Kadia, MD; Farhad Ravandi, MD; Jorge Cortes, MD; Hagop Kantarjian, MD Acute myeloid leukemia (AML) is a heterogeneous disease in its clinical
More informationPublished Ahead of Print on May 31, 2011 as 10.1200/JCO.2010.32.8500. J Clin Oncol 29. 2011 by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on May 31, 11 as 1.1/JCO.1.32.85 The latest version is at http://jco.ascopubs.org/cgi/doi/1.1/jco.1.32.85 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term Prognosis
More informationNovel Approaches to the Treatment of Acute Myeloid Leukemia
ACUTE MYELOID LEUKEMIA IN THE AGE OF GENOMICS Novel Approaches to the Treatment of Acute Myeloid Leukemia Gail J. Roboz 1 1 Weill Medical College of Cornell University, New York, NY Approximately 12 000
More informationA Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly
Clinical Therapeutics/Volume 33, Number 3, 2011 A Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly Dimitrios C. Ziogas, MD 1,2 ; Michael
More informationEarly mortality rate (EMR) in Acute Myeloid Leukemia (AML)
Early mortality rate (EMR) in Acute Myeloid Leukemia (AML) George Yaghmour, MD Hematology Oncology Fellow PGY5 UTHSC/West cancer Center, Memphis, TN May,1st,2015 Off-Label Use Disclosure(s) I do not intend
More informationHematologic Malignancies
Hematologic Malignancies Elizabeth A. Griffiths, MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationAcute Myeloid Leukemia
The new england journal of medicine Review Article Dan L. Longo, M.D., Editor Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. From the Department of
More informationAcute Myeloid Leukemia in Adults: Is Postconsolidation Maintenance Therapy Necessary?
Progress in Hematology International Journal of HEMATOLOGY Acute Myeloid Leukemia in Adults: Is Postconsolidation Maintenance Therapy Necessary? Thomas Büchner, a, * Wolfgang Hiddemann, b Bernhard Wörmann,
More informationA multicenter phase III trial HOVON 132 AML / SAKK 30/13 PROTOCOL. Principal Investigator : B. Löwenberg Sponsor : HOVON
Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged
More informationEffect of lymphocyte count and AML prognosis. Hanahlyn Park. A thesis. submitted in partial fulfillment of the. requirements for the degree of
Effect of lymphocyte count and AML prognosis Hanahlyn Park A thesis submitted in partial fulfillment of the requirements for the degree of Master of Nursing University of Washington 2014 Committee: Kathleen
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationThe evolving role of stem cell transplantation in acute promyelocytic leukemia
The evolving role of stem cell transplantation in acute promyelocytic leukemia 1 S.M. Ramadan, 2 L. Cicconi, 1, 3 F. Lo-Coco I Simposio Conjunto EHA - SAH 1Department of Biomedicine and Prevention, University
More informationAr Mino changes including adjustment of therapy algorithms
cute Myeloid Leukemia Updated April 2008 by Dr. Richard Wells* Updates: Ar Mino changes including adjustment of therapy algorithms Introduction Acute myeloid leukemia is a relatively uncommon cancer with
More informationEBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 356 CHAPTER 20. HSCT for acute myeloid leukaemia in adults. R. Varaldo, F. Frassoni
EBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 356 * CHAPTER 20 HSCT for acute myeloid leukaemia in adults R. Varaldo, F. Frassoni EBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 357 CHAPTER 20 AML in adults
More informationrevisiones0 Importance of genetics in acute myeloid leukemia Papel de la genética en la leucemia mieloide aguda R. Pippa, M.D.
revisiones0 Importance of genetics in acute myeloid leukemia Papel de la genética en la leucemia mieloide aguda R. Pippa, M.D. Odero ABSTRACT Acute myeloid leukemia (AML) comprises a biologically and clinically
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationMyeloablative conditioning regimens for the
ACUTE MYELOID LEUKEMIA What is the role of reduced-intensity transplantation in the treatment of older patients with AML? Stephen J. Forman 1 1 Department of Hematology and Hematopoietic Cell Transplantation,
More informationDaiichi Sankyo to Acquire Ambit Biosciences
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
More informationGuideline 12-9. A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)
Guideline 12-9 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment of Acute Myeloid Leukemia (AML) Andre C Schuh, Glenn G Fletcher, Brian Leber,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Jeffrey E. Rubnitz, MD, PhD a, *, Brenda Gibson, MD b, Franklin O. Smith, MD c KEYWORDS Myeloid Leukemia Childhood Acute myeloid leukemia (AML) is a heterogeneous group of leukemias
More informationGenetic Abnormalities and Challenges in the Treatment of Acute Myeloid Leukemia
Review Genetic Abnormalities and Challenges in the Treatment of Acute Myeloid Leukemia Genes & Cancer 2(2) 95 107 The Author(s) 2011 Reprints and permission: sagepub.com/journalspermissions.nav DOI: 10.1177/1947601911408076
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationHow I treat refractory and early relapsed acute myeloid leukemia
How I Treat From www.bloodjournal.org by guest on July 23, 2015. For personal use only. How I treat refractory and early relapsed acute myeloid leukemia Felicitas Thol, 1 Richard F. Schlenk, 2 Michael
More informationSelection of the Optimal Umbilical Cord Blood Unit
Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies
More informationConcise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia
CANCER STEM CELLS Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia BETTY K. HAMILTON, EDWARD A. COPELAN Department of Hematologic Oncology,
More informationPoročilo EHA 2012. Simon Bitežnik
Poročilo EHA 212 Simon Bitežnik 1 Burden of chronic anaemia in patients with MDS Anaemia is a major clinical problem in patients with MDS ~8% patients are anaemic at diagnosis 1 In patients with MDS, anaemia
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationBiometrische Aspekte der Studien zur akuten myeloischen Leukämie: Sequentielle Verfahren und Evaluation prognostischer Faktoren
Biometrische Aspekte der Studien zur akuten myeloischen Leukämie: Sequentielle Verfahren und Evaluation prognostischer Faktoren Dipl.-Math. C. Sauerland (sauerla@uni-muenster.de) Dipl.-Biomath. S. Amler
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationEISAI INC. FDA ODAC BRIEFING DOCUMENT NDA 021790/S-010. DACOGEN (decitabine) INDICATION: ACUTE MYELOID LEUKEMIA MEETING DATE: FEBRUARY 09, 2012
EISAI INC. FDA ODAC BRIEFING DOCUMENT NDA 021790/S-010 DACOGEN (decitabine) INDICATION: ACUTE MYELOID LEUKEMIA MEETING DATE: FEBRUARY 09, 2012 ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC
More informationPerspectives on the Treatment of Acute Myeloid Leukemia
Perspectives on the Treatment of Acute Myeloid Leukemia LORI J. MANESS, MD Assistant Professor of Medicine University of Nebraska Medical Center College of Medicine Section of Oncology/Hematology Omaha,
More informationBoolean Implications Identify Wilms Tumor 1 Mutation as a Driver of DNA Hypermethylation in Acute Myeloid Leukemia
Boolean Implications Identify Wilms Tumor 1 Mutation as a Driver of DNA Hypermethylation in Acute Myeloid Leukemia Subarna Sinha PhD Department of Computer Science Principal Investigator: David Dill Daniel
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationTherapeutic Options in the Management of Acute Myelogenous Leukemia in Adults
Therapeutic Options in the Management of Acute Myelogenous Leukemia in Adults Ruben A. Saez, MD Several advances in evaluation and treatment have improved the prognosis of adults with acute myelogenous
More informationAge-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group
VOLUME 27 NUMBER 1 JANUARY 1 29 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T From the Departments of Hematology and Oncology and Medical Informatics and Biomathematics, University of Münster,
More informationNovel therapies for children with acute myeloid leukaemia
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Novel therapies for children with acute myeloid leukaemia Authors: Andrew S. Moore PhD 1,2,3, Pamela R. Kearns PhD 4,5, Steven Knapper
More informationEvaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia
Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Dr Jordi Sierra Gil IRHSP Institut de Recerca Hospital de la Santa Creu i Sant Pau Dr. Miguel Ángel Sanz Alonso Fundación
More informationOncologist. The. Pediatric Oncology. Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
The Oncologist Pediatric Oncology Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia SOHEIL MESHINCHI, a ROBERT J. ARCECI b a Fred Hutchinson Cancer Research Center, University
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More information6th edi(on Highlights from EHA Leucemia acuta linfoblas6ca
6th edi(on Highlights from EHA Leucemia acuta linfoblas6ca HOT QUESTIONS ü Which Biomarkers in ALL? ü Will NGS be the future standard for MRD? ü Which are the most promising new drugs in ALL? ü What about
More information[ NASDAQ: MEIP ] Bank of America Merrill Lynch Health Care Conference May 12-14, 2015
[ NASDAQ: MEIP ] Bank of America Merrill Lynch Health Care Conference May 12-14, 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements.
More informationCytarabine Dose for Acute Myeloid Leukemia
original article Cytarabine Dose for Acute Myeloid Leukemia Bob Löwenberg, M.D., Thomas Pabst, M.D., Edo Vellenga, M.D., Wim van Putten, M.Sc., Harry C. Schouten, M.D., Carlos Graux, M.D., Augustin Ferrant,
More informationState of the Art Therapy of Acute Promyelocytic Leukemia
State of the Art Therapy of Acute Promyelocytic Leukemia Francesco Lo-Coco, MD University Tor Vergata, Rome; GIMEMA Cooperative Group, Italy DGHO Annual Congress Hamburg, October 10-14, 2014 Outline Early
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Frederick R. Appelbaum, Jacob M. Rowe, Jerald Radich, and John E. Dick Through the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming
More informationcancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146
Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer
More informationShaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological
An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly
More informationThe prevalent predicament of relapsed acute myeloid leukemia
ACUTE MYELOID LEUKEMIA: NEWLY DISCOVERED GENES, SCREENS (FOR MINIMAL RESIDUAL DISEASE), AND THERAPEUTIC MEANS The prevalent predicament of relapsed acute myeloid leukemia Jeffrey Szer 1 1 Department of
More informationMultiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
Multiple Myeloma: Novel Agents Robert A. Kyle, M.D. Germany June 28, 2008 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma Untreated Initial Therapy Transplant eligible Multiple
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationTargeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014
Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationMatthew Ulrickson, MD Banner MD Anderson Cancer Center July 29, 2015
Matthew Ulrickson, MD Banner MD Anderson Cancer Center July 29, 2015 Discuss the clinical presentation and diagnosis of acute leukemia * Discuss the impact of molecular features on prognosis and management
More informationAcute myeloid leukaemia - therapy - past, present and future
Acute myeloid leukaemia - therapy - past, present and future Paul Faduola 1, Alan Hakim, Juli Mansnérus 1, Atsuko Imai 1, Rob O Neill 2 1 University of Edinburgh. 2 Edinburgh Cancer Research Centre. *
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationUpdate on Follicular Lymphoma. Brad Kahl, M.D.
Update on Follicular Lymphoma Brad Kahl, M.D. Follicular Lymphoma: 25% of NHL Cases Other subtypes (9%) T and NK cell (12%) Burkitt (2.5%) Diffuse large B cell (DLBCL) (30%) Mantle cell (6%) Follicular
More informationShould we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,
More informationtrial update clinical
clinical trial update by John W. Mucenski, B.S., Pharm.D., director of pharmacy operations, UPMC Cancer Centers Therapies for relapsed or refractory leukemias are limited. Research into small molecules
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More information